Giuseppe Sanguineti
Johns Hopkins University
CancerInternal medicineRadiologyUrologySurgeryOncologyRetrospective cohort studyRandomized controlled trialMedical physicsHead and neck cancerChemotherapyHead and neck squamous-cell carcinomaCarcinomaConcomitantProstate cancerLarynxToxicityNuclear medicineRadiation therapyMedicine
Publications 265
#1Laura PizzutiH-Index: 20
#2Maddalena BarbaH-Index: 31
Last. Clara Natoli (University of Chieti-Pescara)H-Index: 32
view all 0 authors...
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. Data of patients affected by HER2-positive mBC, treated with pertuzumab and/or trastuzumab-emtansine (T-DM1) in a real-world settin...
#1Fernando Munoz (AUSL: Academy for Urban School Leadership)H-Index: 11
#2Giuseppe SanguinetiH-Index: 37
Last. A. FaiellaH-Index: 5
view all 0 authors...
Background: Baseline urinary incontinence (UI) strongly modulates UI recovery after adjuvant/salvage radiotherapy (ART/SRT), inducing clinicians to postpone it “as much as possible”, maximizing UI recovery but possibly reducing efficacy. This series aims to analyze the trend of UI recovery and its predictors at radiotherapy start. Methods: A population of 408 patients treated with ART/SRT enrolled in a cohort study ( #NCT02803086) aimed at developing predictive models of radiat...
PURPOSE The purpose of this study is to evaluate inter- and intra-fraction organ motion as well as to quantify clinical target volume (CTV) to planning target volume (PTV) margins to be adopted in the stereotactic treatment of early stage glottic cancer. METHODS AND MATERIALS Stereotactic body radiotherapy (SBRT) to 36 Gy in 3 fractions was administered to 23 patients with early glottic cancer T1N0M0. Patients were irradiated with a volumetric intensity modulated arc technique delivered with 6 M...
#1Francesco DionisiH-Index: 7
#2L. WidesottH-Index: 13
Last. Giuseppe SanguinetiH-Index: 37
view all 0 authors...
#1Anna Giovanetti (ENEA)H-Index: 10
#2Raffaella MarconiH-Index: 6
Last. Lidia StrigariH-Index: 32
view all 21 authors...
A radiological or nuclear attack could involve such a large number of subjects as to overwhelm the emergency facilities in charge. Resources should therefore be focused on those subjects needing immediate medical attention and care. In such a scenario, for the triage management by first responders, it is necessary to count on efficient biological dosimetry tools capable of early detection of the absorbed dose. At present the validated assays for measuring the absorbed dose are dicentric chromoso...
#1Eriseld KrasniqiH-Index: 7
#2Maddalena BarbaH-Index: 31
Last. Patrizia ViciH-Index: 31
view all 25 authors...
Human papillomaviruses (HPVs) are associated with invasive malignancies, including almost 100% of cervical cancers (CECs), and 35–70% of oropharyngeal cancers (OPCs). HPV infection leads to clinical implications in related tumors by determining better prognosis and predicting treatment response, especially in OPC. Currently, specific and minimally invasive tests allow for detecting HPV-related cancer at an early phase, informing more appropriately therapeutical decisions, and allowing for timely...
1 CitationsSource
#1Giuseppe SanguinetiH-Index: 37
#2Raul PelliniH-Index: 21
Last. Valeria LandoniH-Index: 20
view all 10 authors...
AIM Because the clinical feasibility of stereotactic body radiotherapy (SBRT) for early glottic cancer (T1) is controversial, we report dosimetric results in 27 consecutive patients from a prospective phase I and II study that started in 2017. METHODS In our approach, only the parts of the true vocal cord containing cancer and those immediately adjacent are planned to be treated to 36 Gy and 30 Gy, respectively, in 3 fractions. Several dosimetric metrics for both target volumes and organs at ris...
#1Federica GanciH-Index: 16
#2Matteo AllegrettiH-Index: 7
Last. Giovanni BlandinoH-Index: 66
view all 9 authors...
Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 ye...